For years, investor attention on the booming GLP-1 weight-loss drug market has fixated on Novo Nordisk’s early-mover advantage and U.S. market dynamics, overshadowing Eli Lilly (LLY)’s quiet takeover of the global metabolic treatment space. Yet Wall Street’s persistent oversight of Lilly’s full-spectrum strengths has created a critical market mispricing, according to Morgan Stanley, which has issued a strong endorsement of the pharmaceutical giant’s long-term growth trajectory. Far from a late follower in the GLP-1 race, Lilly has built a multi-layered competitive moat spanning superior product efficacy, diversified global markets, differentiated formulation strategies and a robust pipeline — strengths that position it to sustain industry leadership through the end of the decade.
At the core of Lilly’s outperformance is its sustained edge in therapeutic efficacy, rooted in a differentiated targeting strategy that sets it apart from Novo Nordisk’s single-focus GLP-1 approach. While Novo Nordisk’s flagship Wegovy operates solely on the GLP-1 hormonal pathway to regulate appetite and blood sugar, Lilly’s blockbuster tirzepatide acts as a dual GLP-1/GIP receptor agonist, activating two key metabolic pathways to deliver markedly superior weight-loss outcomes. Head-to-head 72-week clinical data underscores the gap: Lilly’s Zepbound, approved for chronic weight management, drove an average 20% body weight reduction in patients, compared with just 13% for Wegovy.
Lilly’s technological lead is set to widen further with its next-generation candidate retatrutide, a triple-pathway therapy that has delivered transformative Phase III trial results. In an 80-week study of patients with obesity and comorbid conditions, the highest retatrutide dose yielded an average 28% body weight loss, with 45% of participants shedding more than 30% of their body weight — results nearing the efficacy of surgical weight-loss procedures. Morgan Stanley stresses that this staged, incremental advancement from dual to triple-target innovation creates a generational technological gap, leaving peer competitors scrambling to catch up while Lilly controls the upper tier of the high-efficacy weight-loss market.
Compounding Lilly’s product edge is a resilient global business ecosystem that investors have largely overlooked in their singular focus on the firm’s 60% share of the U.S. GLP-1 market. Per Morgan Stanley’s latest industry analysis, Lilly commands more than 53% of the worldwide GLP-1 market, with dominant stakes of roughly 60% in high-growth markets including Brazil and South Korea, and a sustained share above 55% in Europe following the 2024 launch of its obesity treatment indications.
The firm’s standout resilience is best exemplified by its performance in India, a critical test case for brand power amid generic competition. After Novo Nordisk’s Wegovy lost patent protection in the region, low-cost generic alternatives flooded the market, pressuring industry-wide pricing. Even amid this disruption, sales of Lilly’s diabetes and weight-loss drug Mounjaro rose 10% year-over-year, defying broad market expectations. Morgan Stanley attributes the outperformance to unshakable brand stickiness: consumers prioritizing proven superior efficacy remain willing to pay a premium for Lilly’s branded products, despite cheaper generic alternatives.
Lilly’s global growth momentum is reflected in its robust 2026 first-quarter financial results. Mounjaro’s global revenue surged 125% year-over-year, while Zepbound sales climbed 80%, with international markets outpacing U.S. domestic growth by a wide margin. This dual growth engine — balancing mature U.S. demand and fast-growing overseas markets — has insulated Lilly from regional market volatility, delivering far greater business stability than many industry peers.
Lilly has also outmaneuvered rivals through agile formulation innovation, addressing a key consumer pain point to expand its addressable market. When Novo Nordisk captured early headlines with the first oral GLP-1 pill, Lilly quickly countered with the launch of its oral candidate Foundayo, establishing direct competition in the non-injectable segment. Crucially, the two firms adopted divergent product strategies: Novo Nordisk’s oral drug uses the same formula as its injectable Wegovy, while Lilly engineered an entirely new molecular entity for Foundayo. Though the oral version is slightly less potent than Lilly’s injectable portfolio, the new formulation caters to injection-averse patients, broadening its consumer base and solidifying its full-market coverage. Morgan Stanley notes that this dual injectable-and-oral ecosystem allows Lilly to serve diverse patient preferences, locking in market share across all consumer segments.
Despite its dominant market position and high-growth trajectory, Lilly’s valuation remains subdued, presenting a compelling risk-reward profile for long-term investors. The stock trades at a forward price-to-earnings ratio of approximately 38x, a steep discount to its five-year average of 56x and a disconnect relative to the GLP-1 sector’s multi-billion-dollar long-term market potential. Morgan Stanley argues the market has materially underpriced Lilly’s growth runway, projecting that the firm’s GLP-1 product portfolio will exceed $60 billion in annual revenue by 2030.
The muted valuation, paired with accelerating pipeline and geographic growth, underpins the investment bank’s bullish stance. Morgan Stanley maintains an “Overweight” rating on Lilly stock with a target price above $1,300, framing the firm as a rare high-growth, high-certainty play in the global healthcare sector. For growth investors, Lilly stands at a unique inflection point, poised for simultaneous valuation re-rating and earnings expansion.
Once a secondary player trailing Novo Nordisk in the early GLP-1 market, Lilly has engineered a remarkable industry turnaround. Its ascent stems not from isolated product wins, but from a cohesive three-pillar strategy: industry-leading therapeutic innovation, resilient global market penetration, and diversified product formulation. As the global weight-loss drug market scales toward a multi-billion-dollar valuation, Lilly has redefined the benchmark for metabolic disease treatment — and according to Morgan Stanley, its full market potential has yet to be priced in by Wall Street.
